Demirkan, F. G. Et Al. 2022. Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group.. Expert opinion on biological therapy , vol.22, no.2 , 197-202.

Demirkan, F. G., Ulu, K., Öztürk, K., Karadağ, Ş. G., Özdel, S., Sönmez, H. E., ... Çakmak, F.(2022). Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group.. Expert opinion on biological therapy , vol.22, no.2, 197-202.

Demirkan, Fatma Et Al. "Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group.," Expert opinion on biological therapy , vol.22, no.2, 197-202, 2022

Demirkan, Fatma G. Et Al. "Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group.." Expert opinion on biological therapy , vol.22, no.2, pp.197-202, 2022

Demirkan, F. G. Et Al. (2022) . "Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group.." Expert opinion on biological therapy , vol.22, no.2, pp.197-202.

@article{article, author={Fatma Gül DEMİRKAN Et Al. }, title={Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group.}, journal={Expert opinion on biological therapy}, year=2022, pages={197-202} }